Targeting RAS in Pancreatic Cancer: Is the "Undruggable" Era Finally Over?

Name: Targeting RAS in Pancreatic Cancer: Is the "Undruggable" Era Finally Over?
Uploaded: 2026-06-01T18:21:41.597+00:00
Duration: 18 min 49 s
Description: For decades, targeting RAS in pancreatic cancer was deemed "undruggable"—until now.

For decades, targeting RAS in pancreatic cancer was deemed "undruggable"—until now. With groundbreaking Phase 3 RASOLUTE trial data shaking up the treatment landscape, are next-generation pan-RAS inhibitors finally delivering the breakthrough clinicians and patients have been waiting for? Read the full accompanying article on Oncology Data Advisor: Pancreatic cancer remains a profound clinical challenge, but a new class of targeted therapies is rewriting the treatment landscape. In this episode, Gastrointestinal Oncologist Dr. Christos Fountzilas and Hematology/Oncology Fellow Dr. Waqas Haque break down the emerging science, biomarker-driven strategies, and toxicity management behind the novel pan-RAS inhibitor, daraxonrasib. Discover how these biology-driven designs are moving past old limitations to expand options for advanced pancreatic cancer care. What You’ll Learn in This Episode: ● From "Undruggable" to Opportunity: How broader strategies, like pan-RAS inhibitors, are expanding treatment options for more patients. ● Clinical Trial Spotlight: Early signals from the phase 3 RASOLUTE trial evaluating the investigational pan-RAS inhibitor daraxonrasib. ● Biomarker Testing & Patient Selection: Why comprehensive molecular profiling (somatic, liquid, and germline) is essential at advanced diagnosis. ● Managing Toxicities: How to interpret preliminary data and proactively manage gastrointestinal and dermatologic side effects. ● The Future of RAS Therapy: Why treatment strategies must remain grounded in tumor biology to build effective combination therapies. About the Speakers: Christos Fountzilas, MD, FACP: A Gastrointestinal Medical Oncologist and early-phase clinical trial investigator at @roswellparkofficial. Waqas Haque, MD, MPH: A Hematology/Oncology Fellow at the @UChicago specializing in innovative clinical trial design, value-based care delivery, and clinical investigation. Stay Connected: Subscribe for more deep dives into oncology research and practice.